MS Detection of Somatic Mutations in Hematological Malignancies

University Hospital, Strasbourg, France200 enrolled

Overview

Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limitation for its availability. An original approach is now available, using mass spectrometry (MS). In this study the analytical performance of both methods will be compared, using samples that were previously analyzed by NGS. The goal of the study is to assess whether MS can represent or not a faster and cheaper way to detect key point mutations in patients suffering from hematological malignancies

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Hematological Malignancy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adults \>18 years old * anonymized samples already studied with NGS in Strasbourg university hematology center for somatic mutations * non-opposition of the patient for testing the archive sample with the new method Exclusion Criteria: * opposition for testing the archive sample with the new method * insufficient archival material * patient under protection

Locations (1)

Laboratoire d'Hématologie

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Detection of somatic mutations in hematological malignancies by using mass spectrometry (MS)

Time frame: 10 months

Central Contacts

Laurent MAUVIEUX, MD, PhD

CONTACT

33 3 88 12 75 27 laurent.mauvieux@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.